Great Basin Scientific (GBSN) Plans Demonstration of Molecular Diagnostics Platform at AMP 2016

November 10, 2016 7:04 AM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

reat Basin Scientific, Inc. (OTC: GBSN) will demonstrate its molecular diagnostics platform at the Association for Molecular Pathology (AMP) 2016 Annual Meeting in Charlotte, North Carolina, November 10-12. At booth 302, the Company will show conference attendees the ease-of-use and simple workflow of its sample-to-result system, designed to help small to medium-sized hospitals reduce costs and provide better patient outcomes.

In addition to the exhibition, Great Basin Scientific’s technology will be presented with clinical study findings in a poster titled “Implementation of the Great Basin Group B Streptococcus (GBS) Assay using Hardy Carrot Broth in a Community Hospital Laboratory,” selected to be presented within the Infectious Diseases category. The study findings demonstrate the feasibility of carrot broth testing on the Great Basin system, a sample type not included in Great Basin’s GBS clinical trial. The demonstrated feasibility of carrot broth as a specimen culture media potentially expands the utility and market opportunity of the Company’s GBS test at hospitals and labs using carrot broth enrichment for patient samples.

The presenting author will be available during the poster session in the Exhibit Hall on Friday, November 11, 2:30pm – 3:30pm ET. Further, the poster will be available for download from the Great Basin website after the close of the Annual Meeting.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Related Entities

Twitter

Add Your Comment